Total Funding
48
62
Total FundingNon-equity Assistance raised
Growth Score 48 in past quarter
-10 pts
Heat Score 62 in past quarter
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
32611
Prevencio is a developer of multi-proteomic biomarkers designed to revolutionize blood tests for cardiovascular disease.
- Michele McCarthy: Chief Financial OfficerPast Role: Ernst & Young, Audit Specialist
- Celine Peters: VP, Clinical Market Development
About the Company
Prevencio is a developer of multi-proteomic biomarkers designed to revolutionize blood tests for cardiovascular disease. The company's biomarkers employ artificial intelligence to interrogate well-characterized clinical data sets to produce novel, multi-protein, algorithmically-scored tests, enabling clinicians to assess
pre-drug/post-drug effects on a composite of heart attack, stroke and cardiac death.
Women Founded
Women Led
